DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models

Zhen Chen(Chongqing Medical University), Shi‐Yong Sun(Emory University)

Journal of Clinical Investigation

March 7, 2024

10.1172/jci172716

Cited by 28

Related Papers

Effects of Deguelin on the Phosphatidylinositol 3-Kinase/Akt Pathway and Apoptosis in Premalignant Human Bronchial Epithelial Cells

|JNCI Journal of the National Cancer Institute|2003|257

Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance

|Proceedings of the National Academy of Sciences|2014|177

The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells

|Cancer Research|2007|164

Enhancing Mammalian Target of Rapamycin (mTOR)–Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation

|Cancer Research|2008|159

Inhibition of IκB Kinase-Nuclear Factor-κB Signaling Pathway by 3,5-Bis(2-flurobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin

|Molecular Pharmacology|2008|158